Meridiem Capital Partners LP Buys New Position in RxSight, Inc. $RXST

Meridiem Capital Partners LP bought a new stake in shares of RxSight, Inc. (NASDAQ:RXST) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 174,014 shares of the company’s stock, valued at approximately $1,564,000. Meridiem Capital Partners LP owned 0.42% of RxSight at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RXST. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of RxSight by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,861 shares of the company’s stock valued at $552,000 after acquiring an additional 1,232 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in RxSight by 57.9% during the first quarter. Goldman Sachs Group Inc. now owns 310,411 shares of the company’s stock worth $7,838,000 after purchasing an additional 113,767 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in RxSight by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 93,382 shares of the company’s stock worth $2,358,000 after purchasing an additional 8,424 shares during the period. SG Americas Securities LLC lifted its position in RxSight by 83.6% in the second quarter. SG Americas Securities LLC now owns 66,600 shares of the company’s stock worth $866,000 after purchasing an additional 30,333 shares during the period. Finally, Creative Planning bought a new position in RxSight during the 2nd quarter valued at $207,000. 78.78% of the stock is currently owned by institutional investors.

RxSight Trading Up 1.3%

RXST stock traded up $0.10 during mid-day trading on Friday, reaching $7.74. 49,521 shares of the stock traded hands, compared to its average volume of 991,975. RxSight, Inc. has a 52-week low of $6.32 and a 52-week high of $27.13. The stock’s fifty day moving average is $8.74 and its 200-day moving average is $9.43. The company has a market cap of $319.28 million, a P/E ratio of -8.11 and a beta of 1.16.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RXST. Needham & Company LLC reissued a “buy” rating and issued a $13.00 price objective on shares of RxSight in a research note on Thursday, February 26th. Stifel Nicolaus decreased their target price on RxSight from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Monday. UBS Group lifted their target price on RxSight from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Thursday, February 26th. Wolfe Research upgraded shares of RxSight to an “outperform” rating in a research report on Friday, January 30th. Finally, Morgan Stanley upped their price target on shares of RxSight from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $9.78.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.